1-(8,9-dihydroxynonyl)-3,7-dimethylxanthine | 156918-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-(8,9-dihydroxynonyl)-3,7-dimethylxanthine
• 英文别名: 1-(8,9-dihydroxynonyl)-3,7-dimethylpurine-2,6-dione
• CAS: 156918-12-6
• 化学式: C₁₆H₂₆N₄O₄
• 分子量: 338.407
• InChiKey: ZINZBKGLWCNGTJ-UHFFFAOYSA-N

物化性质

• 沸点：
  598.6±58.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  98.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(8,9-dihydroxynonyl)-3,7-dimethylxanthine 在 氢溴酸 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 溶剂黄146 为溶剂， 以96%的产率得到1-(8-acetoxy-9-bromononyl)-3,7-dimethylxanthine
  参考文献：
  名称：

  Substituted amino alcohol compounds

  摘要：

  本文揭示了具有公式I的直链或支链脂肪烃结构的化合物：##STR1## 在公式I中，n是一个从一到四的整数，m是一个从四到二十的整数。独立地，R.sub.1和R.sub.2是氢，长度最多为二十个碳原子的直链或支链烷基，烯基或炔基，或者是--(CH.sub.2).sub.w R.sub.5。如果R.sub.1或R.sub.2是--(CH.sub.2).sub.w R.sub.5，w可以是一个从一到二十的整数，R.sub.5可以是一个羟基，卤素，C.sub.1-8烷氧基团或一个取代或未取代的碳环或杂环。另外，R.sub.1和R.sub.2可以共同形成一个取代或未取代的，饱和或不饱和的，由四到八个碳原子组成的杂环，N是所得杂环的杂原子。R.sub.3可以是氢或C.sub.1-3。在化合物中，包括R.sub.1或R.sub.2，(CH.sub.2).sub.n和(CH.sub.2).sub.m的碳原子总和不超过四十。R.sub.4是一个末端基团，包括一个取代或未取代的，氧化或还原的环系统，该环系统具有单环或两到三个融合环，一个环包含三到七个环原子。所述化合物是有效的抑制细胞刺激引起的不良反应的药剂。

  公开号：

  US05641783A1
• 作为产物：
  描述：

  可可碱 在 OsO4 N-甲基吗啉氧化物 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 、 丙酮 、 叔丁醇 为溶剂， 生成 1-(8,9-dihydroxynonyl)-3,7-dimethylxanthine
  参考文献：
  名称：

  Substituted long chain alcohol xanthine compounds

  摘要：

  本发明涉及化合物和制药组合物，其包括以下结构的化合物：##STR1## 其中一个或两个R中的每一个独立地是##STR2## 其中n是从7到20的整数，X或Y中至少一个是--OH，如果X或Y中的一个是--OH，则另一个X或Y是H，CH.sub.3，CH.sub.3 --CH.sub.2，CH.sub.3 --(CH.sub.2).sub.2 --或(CH.sub.3).sub.2 --CH.sub.2 --，W.sub.1，W.sub.2和W.sub.3独立地是H，CH.sub.3，CH.sub.3 --CH.sub.2，CH.sub.3 --(CH.sub.2).sub.2 --或(CH.sub.3).sub.2 --CH.sub.2 --，其中烷基基团可以被羟基，卤素或二甲氨基基团取代和/或由氧原子，H或烷基（1-4C）中断，包括已分离的对映异构体和/或二面体异构体，盐和混合物。特别地，这些化合物在主要刺激和它们与细胞接触的几秒钟内降低了源自所述PA的不饱和非花生四烯酸磷脂酸（PA）和二酰基甘油（DAG）的升高水平。调节作用取决于目标细胞的性质和施加的刺激。

  公开号：

  US05473070A1

文献信息

• Methods for using therapeutic compounds containing xanthinyl
  申请人：Cell Therapeutics, Inc.

  公开号：US06043250A1

  公开（公告）日：2000-03-28

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(.sub.1-10) alkyl, C(.sub.2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C(.sub.1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or 0, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  具有至少一个羧酸、酯或酰胺取代侧链的治疗化合物具有以下公式：CORE MOIETY --(R).sub.j，其中j是从一到三的整数。核心基团是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C(.sub.1-10)烷基、C(.sub.2-10)烯基、碳环或杂环基团中选择，至少一个R具有以下公式I：##STR1##其中：一个或两个p是整数一，否则p为二；n是从三到二十的整数；R.sub.1从取代和未取代的CH.sub.2；NR.sub.3中选择，R.sub.3为氢、取代或未取代的C(.sub.1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基或C.sub.(1-20)羟基烷基，或碳环或杂环基团；O；--CHR.sub.4 O--，R.sub.4为取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基、C.sub.(1-20)羟基烷基，或R.sub.2和R.sub.4连接形成具有四到七个环原子的取代或未取代杂环，--CHR.sub.4 O--的醚基--O--是杂环的成员。R.sub.2从氢；卤素；取代或未取代的C.sub.(1-10)烷基；C.sub.(1-10)烷氧基；C.sub.(2-10)烯基；C.sub.(1-10)羟基烷基；--A(R.sub.5).sub.m中选择，A为N或0，m为一或二，R.sub.5为氢、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基或C.sub.(1-10)羟基烷基，或碳环或杂环基团。R.sub.1中至少有一个为NR.sub.3、O或--CHR.sub.4 O--，或R.sub.2为--A(R.sub.5).sub.m。这些化合物及其制药组合物可用作通过介导对外部刺激的信号响应来通过特定细胞内信号传导途径推进的疾病的治疗方法。
• Therapeutic compounds containing pyrimidinyl moieties
  申请人：Cell Therapeutics, Inc.

  公开号：US05807862A1

  公开（公告）日：1998-09-15

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY--(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  具有至少一个羧酸、酯或酰胺取代侧链的治疗化合物具有以下公式：CORE MOIETY--(R).sub.j，其中j是从一到三的整数。核心基团是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、碳环或杂环基团中选择，至少一个R具有以下公式I：##STR1##其中：一个或两个p是整数一，否则p是二；n是从三到二十的整数；R.sub.1从取代和未取代的CH.sub.2；NR.sub.3中选择，R.sub.3为氢、取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基或C.sub.(1-20)羟基烷基，或碳环或杂环基团；O；--CHR.sub.4 O--，R.sub.4为取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基、C.sub.(1-20)羟基烷基，或R.sub.2和R.sub.4结合形成具有四到七个环原子的取代或未取代杂环，--CHR.sub.4 O--的醚基--O--是杂环的成员。R.sub.2从氢、卤素、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基、C.sub.(1-10)羟基烷基；--A(R.sub.5).sub.m中选择，A为N或O，m为一或二，R.sub.5为氢、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基或C.sub.(1-10)羟基烷基，或碳环或杂环基团。R.sub.1中至少有一个为NR.sub.3、O或--CHR.sub.4 O--，或R.sub.2为--A(R.sub.5).sub.m。这些化合物及其制药组合物可用作通过介导对外部刺激的信号响应来通过特定细胞内信号传导途径推进的疾病的治疗方法。
• Therapeutic compounds containing xanthinyl
  申请人：Cell Therapeutics, Inc.

  公开号：US06100271A1

  公开（公告）日：2000-08-08

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyallyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  具有至少一个羧酸、酯或酰胺取代侧链的治疗化合物具有以下公式：CORE MOIETY --(R).sub.j，其中j是从一到三的整数。核心基团是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、碳环或杂环基团中选择，至少一个R具有以下公式I：##STR1##其中：一个或两个p是整数一，否则p为二；n是从三到二十的整数；R.sub.1从取代和未取代的CH.sub.2；NR.sub.3中选择，R.sub.3为氢、取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基或C.sub.(1-20)羟基烷基，或碳环或杂环基团；O；--CHR.sub.4 O--，R.sub.4为取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基、C.sub.(1-20)羟基烷基，或R.sub.2和R.sub.4结合形成具有四到七个环原子的取代或未取代杂环，--CHR.sub.4 O--的醚基--O--为杂环的成员。R.sub.2从氢；卤素；取代或未取代的C.sub.(1-10)烷基；C.sub.(1-10)烷氧基；C.sub.(2-10)烯基；C.sub.(1-10)羟基烯基；--A(R.sub.5).sub.m中选择，A为N或O，m为一或二，R.sub.5为氢、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基或C.sub.(1-10)羟基烷基，或碳环或杂环基团。R.sub.1中至少有一个为NR.sub.3、O或--CHR.sub.4 O--，或R.sub.2为--A(R.sub.5).sub.m。这些化合物及其制药组合物可用作通过介导对外部刺激的信号响应来通过特定细胞内信号传导途径推进的疾病的治疗方法。
• Cell signaling inhibitors
  申请人：Cell Therapeutics, Inc.

  公开号：US05470878A1

  公开（公告）日：1995-11-28

  Therapeutic compounds have the formula: (X)j-(non-cyclic core moiety), j being an integer from one to three, the core moiety is non-cyclic and X is a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxy group.

  治疗性化合物的化学式为：(X)j-(非环核心基团)，其中j为1到3之间的整数，核心基团为非环状，X为一个消旋混合物、R或S对映体、溶剂化合物、水合物或盐类：*C为手性碳原子，n为1到4之间的整数（最好为1到3），(CH.sub.2).sub.n的一个或多个碳原子可被酮基或羟基取代，m为1到14之间的整数。独立地，R.sub.1和R.sub.2可以是氢、直链或支链烷烯链，长度最多为12个碳原子，或--(CH.sub.2).sub.w R.sub.5，其中w为2到14之间的整数，R.sub.5为单取代、双取代或三取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基。或者，R.sub.1和R.sub.2共同形成一个取代或未取代、饱和或不饱和的杂环基团，含有4到8个碳原子，N为杂原子。R.sub.3为氢或C.sub.1-3。或者，治疗性化合物也可以具有以下化学式：R.sub.4为氢、直链或支链烷烯链，长度最多为8个碳原子，--(CH.sub.2).sub.w R.sub.5，其中w为2到14之间的整数，R.sub.5为单取代、双取代或三取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基，或者为一个取代或未取代、饱和或不饱和的含有4到8个碳原子的杂环基团。r和s独立地为1到4之间的整数，和不大于5。t为1到14之间的整数，(CH.sub.2).sub.s或(CH.sub.2).sub.t的一个或多个碳原子可被酮基或羟基取代。
• Amino-alcohol substituted cyclic compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05837703A1

  公开（公告）日：1998-11-17

  Therapeutic compounds have the formula: (X)j-(core moiety), j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH.sub.2).sub.m, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkyl or alkenyl of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxyl group.

  治疗化合物的公式为：(X)j-(核心基团)，其中j为从一到三的整数，核心基团包括一个杂环，该杂环具有一个环或两个融合的环，每个环有五个或六个环原子，A是核心基团的碳原子，连接到(CH.sub.2).sub.m的末端碳原子，而X具有结构，X是一个外消旋体混合物，R或S对映体，溶剂化物，水合物或盐，其结构如下：##STR1## *C是一个手性碳原子，n是从一到四的整数（最好从一到三），(CH.sub.2).sub.n中的一个或多个碳原子可能被酮基或羟基取代，m是从一到十四的整数。独立地，R.sub.1和R.sub.2可以是氢，长度为最多十二个碳原子的直链或支链烷基或烯基，或--(CH.sub.2).sub.w R.sub.5，其中w是从二到十四的整数，R.sub.5是一个单取代，二取代或三取代或未取代的芳基，R.sub.5上的取代基是羟基，氯，氟，溴或C.sub.1-6烷氧基。或共同地，R.sub.1和R.sub.2形成一个取代或未取代的，饱和或不饱和的杂环基团，其碳原子数为四到八，N是一个杂原子。R.sub.3是氢或C.sub.1-3。或者，治疗化合物也可以具有以下公式：##STR2## R.sub.4是氢，长度为最多八个碳原子的直链或支链烷基或烯基，--(CH.sub.2).sub.w R.sub.5，其中w是从二到十四的整数，R.sub.5是一个单取代，二取代或三取代或未取代的芳基，R.sub.5上的取代基是羟基，氯，氟，溴或C.sub.1-6烷氧基，或一个取代或未取代的，饱和或不饱和的杂环基团，其碳原子数为四到八，r和s是独立的从一到四的整数，其和（r+s）不大于五。t是从一到十四的整数，(CH.sub.2).sub.s或(CH.sub.2).sub.t中的一个或多个碳原子可能被酮基或羟基取代。